Highlights of genitourinary cancer research presented ...
Recommend Documents
fear and a 'broken hearted' feeling. Although infertility after cancer affects up to 60% of cancer survivors, fertility
the best. Courage. Speak out and step up. Responsibility. Be accountable for our results and resources. Collaboration. W
Aug 19, 2011 - GS6 (86%) or GS3+4 (9%) and all had node negative pT2 disease. ...... reads (FPKM) values were computed using Cufflinks in the Galaxy.
glycoprotein that is consistently expressed in benign and neoplastic prostatic tissue ...... 8 papillary urothelial neoplasms of low malignant potential (PUNLMP), 2.
Arsenic contamination in inland open water ecosystems and risk of arsenic ..... high phosphorous (P) and low iron (Fe) concentrations in irrigation water.
National Investor Relations Institute's highly valued research studies are delivered through niri Analytics, comprehensi
It is unclear why this is the case. VEC researchers are discovering the underlying reasons for this and will use this in
Naveen S. Basappa, MD, FRCPC1; Anil Kapoor, MD, FRCSC2. 1Cross Cancer Institute & University of Alberta, Edmonton, AB, Canada;2CUAJ Associate Editor ...
introduction
Highlights of genitourinary cancer research presented at ASCO 2017 Naveen S. Basappa, MD, FRCPC1; Anil Kapoor, MD, FRCSC2 Cross Cancer Institute & University of Alberta, Edmonton, AB, Canada; 2CUAJ Associate Editor & McMaster University, Hamilton, ON; Canada
1
Cite as: Can Urol Assoc J 2017;11(8Suppl5):S297. http://dx.doi.org/10.5489/cuaj.4839
A
t the 2017 annual meeting of the American Society of Clinical Oncology (ASCO), there was a wealth of new information presented in the field of genitourinary (GU) cancers. The following pages provide a summary of findings of several key studies investigating selected themes in kidney, bladder, and prostate cancers. For kidney, the focus of the summary is on new research with tyrosine kin-
ase inhibitors (TKIs; e.g., pazopanib, sunitinib). In bladder cancer, the summary focuses on immuno-oncology, with highlights of new trials evaluating checkpoint inhibitors in this tumour type. Finally, in prostate cancer, the summary includes synopses of new evidence with the oral hormonal agents abiraterone acetate and enzalutamide. Acknowledgement: The authors would like to thank STA Communications for editorial assistance with this report.
